Becton, Dickinson and Company (BDX) Expected to Announce Quarterly Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) is anticipated to post its Q4 2026 results before the market opens on Thursday, November 5th. Analysts expect Becton, Dickinson and Company to post earnings of $4.07 per share and revenue of $5.11 billion for the quarter. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Individuals can find conference call details on the company’s upcoming Q4 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The business’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.68 earnings per share. On average, analysts expect Becton, Dickinson and Company to post $12.67 EPS for the current fiscal year and $13.24 EPS for the next fiscal year.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $194.91 on Thursday. The firm has a market cap of $53.71 billion, a P/E ratio of 58.71, a price-to-earnings-growth ratio of 13.41 and a beta of 0.21. The business’s 50 day moving average is $186.17 and its 200-day moving average is $170.31. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $200.47.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Weiss Ratings upgraded Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. Wolfe Research started coverage on Becton, Dickinson and Company in a research report on Tuesday, October 20th. They set an “outperform” rating on the stock. UBS Group assumed coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price for the company. Evercore set a $180.00 target price on Becton, Dickinson and Company in a report on Monday, July 6th. Finally, Zacks Research upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $185.07.

Insider Activity

In other news, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 6,907 shares of company stock worth $1,269,128. Corporate insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.